Chronic psychotic disorder with positive, negative, and cognitive symptoms persisting >=6 months.
Also known as: schizophrenia, psychotic disorder, primary psychosis
Overview
A chronic primary psychotic disorder defined by >=1 month of active-phase symptoms (>=2 of delusions, hallucinations, disorganized speech, grossly disorganized/catatonic behavior, negative symptoms — including at least one of the first three) with total disturbance >=6 months including prodromal/residual phases, and significant functional decline.
Epidemiology
Lifetime prevalence ~0.7-1%. Onset typically late teens to mid-20s in males, slightly later in females. Slight male predominance with earlier onset and worse outcomes.
Try two board-style Schizophrenia questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1PsychiatryMedium
A 35-year-old female with schizophrenia has been stable on haloperidol for 2 years but developed tardive dyskinesia. Her psychiatrist wants to switch to an antipsychotic with the lowest tardive dyskinesia risk that is also effective for treatment-resistant schizophrenia. Which of the following agents is most appropriate?
AAripiprazole
BOlanzapine
CRisperidone
DQuetiapine
EClozapine
Reveal answer & full explanation
Correct answer: E — Clozapine
AAripiprazole
BOlanzapine
CRisperidone
DQuetiapine
EClozapine✓
Why Clozapine is correct
Clozapine has the lowest risk of extrapyramidal symptoms (EPS) and tardive dyskinesia of all antipsychotics.
Mechanism: weak D2 blockade (only 60-65%) with strong 5-HT2A antagonism plus H1, M1, and alpha-1 antagonism — accounts for low EPS risk.
It is the only antipsychotic FDA-approved for: (1) treatment-resistant schizophrenia (TRS — defined as failure of 2 adequate antipsychotic trials); and (2) reducing suicidal behavior in schizophrenia/schizoaffective disorder.
Why the others are wrong
Aripiprazole — a partial D2 agonist with low EPS risk, but not approved for treatment-resistant schizophrenia and lacks the clozapine evidence base for TRS (right-concept-wrong-drug).
Quetiapine — relatively low EPS risk, but not indicated for treatment-resistant schizophrenia (anchoring on low EPS alone).
Olanzapine — effective second-generation antipsychotic but carries significant metabolic side effects and is not preferred for TRS (premature closure).
Risperidone — a second-generation antipsychotic that may seem to share the low tardive dyskinesia risk of its class, but its potent, dose-dependent D2 blockade gives it among the highest EPS and tardive dyskinesia liability of the second-generation agents, and it is not indicated for treatment-resistant schizophrenia (assuming all second-generation agents are alike).
Additional high-yield points
Severe neutropenia (agranulocytosis) occurs in approximately 1% of patients on clozapine; absolute neutrophil count (ANC) is monitored per the prescribing information: weekly for 6 months, every 2 weeks for months 6-12, then monthly (the FDA eliminated the Clozapine REMS program in 2025).
Other clozapine side effects: weight gain, metabolic syndrome, myocarditis (early — monitor C-reactive protein (CRP) and troponin), seizures (dose-dependent), excessive salivation, constipation, orthostatic hypotension.
Vesicular monoamine transporter 2 (VMAT2) inhibitors (valbenazine, deutetrabenazine) treat established tardive dyskinesia (TD) in patients who remain on the offending antipsychotic.
Question 2PsychiatryMedium
A 35-year-old male with schizophrenia on olanzapine 20 mg daily for 3 years has gained 35 lbs and now has type 2 diabetes (HbA1c 8.2%). His psychosis is well controlled. Which of the following antipsychotics is most appropriate to switch to in order to reduce metabolic risk?
AClozapine
BQuetiapine
CRisperidone
DAripiprazole
EChlorpromazine
Reveal answer & full explanation
Correct answer: D — Aripiprazole
AClozapine
BQuetiapine
CRisperidone
DAripiprazole✓
EChlorpromazine
Why Aripiprazole is correct
Olanzapine and clozapine carry the highest metabolic burden among antipsychotics (weight gain, type 2 diabetes, dyslipidemia), and this patient has already developed olanzapine-attributable obesity and T2DM with well-controlled psychosis
Aripiprazole, a partial dopamine agonist, has among the lowest metabolic liability of the second-generation agents (along with ziprasidone and lurasidone), making it the preferred switch target to reduce weight and glycemic risk
Per APA/ADA consensus, when antipsychotic-induced metabolic complications develop, switching to a lower-risk agent via gradual cross-taper over 4-6 weeks with relapse monitoring is recommended
The switch should be paired with shared decision-making, lifestyle intervention, and consideration of metformin (best adjunctive evidence for antipsychotic-associated weight gain) rather than presented as risk-free
Why the others are wrong
Risperidone — intermediate metabolic risk; an improvement over olanzapine but not the lowest-risk option, so it is not the best choice here (right-direction-wrong-degree)
Quetiapine — higher metabolic liability than aripiprazole and a poor target in a patient who already has T2DM from olanzapine (confused-with low-risk agent)
Clozapine — carries the highest metabolic risk alongside olanzapine and is reserved for treatment-resistant schizophrenia, so it worsens rather than reduces the problem (right-concept-wrong-drug)
Chlorpromazine — first-generation agents are often assumed to be metabolically neutral, but that holds mainly for high-potency drugs; low-potency chlorpromazine causes substantial weight gain and sedation along with anticholinergic and orthostatic effects, so it would not reduce his metabolic risk the way aripiprazole does (confused-with metabolically neutral first-generation agent)
Additional high-yield points
Adjuncts for antipsychotic-induced weight gain: metformin (best evidence), structured lifestyle intervention, and GLP-1 receptor agonists (emerging evidence)
APA/ADA monitoring: weight/BMI monthly x3 then quarterly; fasting glucose and lipids at baseline, 3 months, then annually
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Schizophrenia outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Family history (first-degree relative ~10% risk; monozygotic twin ~50%)
Advanced paternal age at conception
Obstetric complications, perinatal hypoxia, maternal infection (influenza in second trimester)
Urban upbringing, migration
Cannabis use in adolescence (especially high-potency THC)
Childhood adversity
Pathophysiology
Polygenic disorder with disruption of cortical development and synaptic pruning. Dopaminergic hyperactivity in mesolimbic pathways (positive symptoms) and hypoactivity in mesocortical pathways (negative/cognitive symptoms). NMDA receptor hypofunction, GABAergic interneuron deficits, neuroinflammation. Ventriculomegaly and reduced gray matter volume on imaging.
Clinical presentation
Symptoms
Positive: delusions (often persecutory or referential), hallucinations (auditory most common), disorganized speech (derailment, tangentiality, word salad), grossly disorganized/catatonic behavior
Psychosis due to medical condition — Delirium, autoimmune encephalitis (anti-NMDA), temporal lobe epilepsy, Huntington, B12 deficiency, neurosyphilis
Delusional disorder — >=1 month of non-bizarre delusions without other psychotic symptoms; function otherwise preserved
Schizotypal personality disorder — Lifelong stable odd beliefs, magical thinking, and social discomfort without frank psychosis or a new functional decline
Diagnostic workup
Diagnostic criteria
DSM-5-TR: (A) >=2 of delusions, hallucinations, disorganized speech, grossly disorganized/catatonic behavior, negative symptoms — each for a significant portion of 1 month (or less if treated), with at least one being delusions, hallucinations, or disorganized speech; (B) Marked decline in functioning; (C) Continuous signs >=6 months including >=1 month of active symptoms; (D) Schizoaffective and mood disorders with psychosis excluded; (E) Not attributable to substance or medical condition.
Labs
CBC, BMP, LFTs, TSH, vitamin B12, syphilis serology, HIV
Urine drug screen — essential to exclude substance-induced psychosis
Baseline metabolic labs and ECG (QTc) before antipsychotic
Pregnancy test in women of reproductive age
Consider autoimmune encephalitis workup (anti-NMDA, paraneoplastic panel) for atypical presentations
Imaging
MRI brain in first-episode psychosis to exclude structural lesion, demyelination, encephalitis
EEG if temporal lobe epilepsy or encephalopathy suspected
Diagnostic algorithm
Disorder
Active sx duration
Total duration
Mood overlap
Brief psychotic
1 day - 1 month
<1 month
No
Schizophreniform
1-6 months
<6 months
No
Schizophrenia
>=1 month active
>=6 months
No (or brief)
Schizoaffective
>=1 month
>=2 wks psychosis w/o mood
Major mood episode concurrent
Mood d/o w/ psychosis
Variable
Limited to mood episode
Always
Primary psychotic disorder differentials by duration and mood overlap.
Coordinated specialty care for first-episode psychosis — early intervention improves long-term outcomes; continue antipsychotic maintenance after remission (generally at least 1-2 years after a first episode), since early taper or intermittent dosing raises relapse risk
Psychosocial: family psychoeducation, cognitive remediation, supported employment, social skills training, assertive community treatment
Clozapine — uniquely effective; reduces suicide risk; lowest EPS and tardive dyskinesia risk of any antipsychotic
ANC monitoring per prescribing information (Clozapine REMS eliminated 2025): weekly for 6 months, every 2 weeks for months 6-12, then monthly
Monitor for agranulocytosis, myocarditis (usually in the first 1-2 months: fever, chest pain, tachycardia, elevated troponin/CRP, eosinophilia; stop clozapine), seizures, ileus, metabolic syndrome, sialorrhea
Neutropenia action thresholds (general population): ANC 1000-1499 continue with ANC 3 times weekly; ANC 500-999 interrupt clozapine with daily ANC, may resume once ANC ≥1000; ANC <500 discontinue and generally do not rechallenge; lower thresholds apply in benign ethnic neutropenia
Acute agitation
Verbal de-escalation first; offer PO medication
IM olanzapine, haloperidol with benzodiazepine, or aripiprazole IM if needed
Avoid combining IM olanzapine + IM benzodiazepine (respiratory depression)
Victimization (more often victims than perpetrators of violence)
PANCE pearls
Duration of untreated psychosis predicts outcome — early intervention with coordinated specialty care improves trajectory.
Clozapine is the only antipsychotic with demonstrated efficacy in treatment-resistant schizophrenia and reduces suicide risk; underutilized due to monitoring burden.
NMS: fever, rigidity, autonomic instability, elevated CK, altered mental status — stop antipsychotic, supportive care, consider dantrolene or bromocriptine.
Monitor weight/BMI at baseline, monthly for the first 3 months, then quarterly; BP, fasting glucose/A1c, and lipids at baseline, about 3 months, then annually. Metabolic risk: clozapine/olanzapine > quetiapine/risperidone > aripiprazole/lurasidone/ziprasidone; if metabolic complications develop, cross-taper to a lower-risk agent, add lifestyle intervention, consider metformin, and treat glucose, lipids, and BP.
References
APA 2020 — American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia, 3rd ed. (2020)
CATIE — Lieberman JA et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. NEJM 2005
RAISE — Kane JM et al. Comprehensive Versus Usual Community Care for First-Episode Psychosis. Am J Psychiatry 2016
DSM-5-TR — American Psychiatric Association. DSM-5-TR (2022)
Practice Psychiatry/Behavioral questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.